key: cord-0809102-u5zlfdvs
authors: López-Vilella, Raquel; Sánchez-Lázaro, Ignacio; Trenado, Víctor Donoso; Edo, Silvia Lozano; Dolz, Luis Martínez; Bonet, Luis Almenar
title: COVID 19 and heart transplantation. Initial experience in a tertiary hospital
date: 2021-09-06
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2021.07.054
sha: 279d30df6ced17c142e1b50d7945189fc73bdb29
doc_id: 809102
cord_uid: u5zlfdvs

INTRODUCTION: : COVID 19 is a viral infectious disease caused by the SARS-CoV-2 virus that is affecting the entire world population. The objective of this study is to analyze the repercussion of the disease in a group of patients at risk such as heart transplants. MATERIAL AND METHOD: : From February 2020 to February 2021, heart transplant patients diagnosed with COVID 19 were consecutively included. The total number of transplants in outpatient follow-up at that time was 381. 3 levels of infection were determined. A) Asymptomatic patients or with trivial symptoms without the need for hospital admission (6 patients). B) Patients admitted to the hospital for respiratory symptoms (12 patients). C) Patients with severe symptoms and need for admission to the Critical Care Unit (2 patients). At each risk level, medical performance was different. Thus, group A: Close control, no therapeutic modification. Group B: Reduction of calcineurin inhibitor (CNI) and substitution of mycophenolate mofetil (MMF) for everolimus (EVE). Group C: Reduction of ICN and withdrawal of MMF. RESULTS: : The prevalence of infection in the serie was 5.2%. Most of the patients admitted presented a pathological chest X-ray with fever, cough, dyspnea, or vomiting. The change in immunosuppression performed in group 2 patients was well tolerated and there was no graft rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was 50% in group 2 and 100% in group 3. CONCLUSIONS: : A significant number of transplant patients will be affected by COVID19 (5.3%). The management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiological situation, and treatment of the infection.

1 COVID 19 and heart transplantation. Initial experience in a tertiary hospital Raquel López-Vilella (1, 2) , Ignacio Sánchez-Lázaro (1, 2, 3) , Víctor Donoso Trenado (1, 2) , Silvia Lozano Edo (2) , Luis Martínez Dolz (2, 3) , Luis Almenar Bonet (1, 2, 3, 4) .

(1) Heart Failure and Transplant Unit. La Fe University and Polytechnic Hospital. Valencia, Spain.

(2) Department of Cardiology. La Fe University and Polytechnic Hospital. Valencia, Spain. Results: The prevalence of infection in the serie was 5.2%. Most of the patients admitted presented a pathological chest X-ray with fever, cough, dyspnea, or vomiting. The change in immunosuppression performed in group 2 patients was well tolerated and there was no graft rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was 50% in group 2 and 100% in group 3.

Conclusions: A significant number of transplant patients will be affected by COVID19 (5.3%). The management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiological situation, and treatment of the infection.

Coronavirus disease (COVID 19) is an infectious disease caused by a newly discovered virus. Most people who become ill with COVID 19 experience mild to moderate symptoms and recover without special treatment. However, some subgroups of patients, such as heart transplant patients, may 3 experience due to their immunosuppressed condition more severe infection and higher mortality.

Thus, heart transplant patients constitute a vulnerable group to COVID19 and also complex due to the challenge of simultaneously managing infection and immunosuppression to avoid rejection.

The objective of this study was to present the series of cases of heart transplant patients with COVID 19 in a third-level transplant hospital and the attitude taken according to the patient's risk. Figure 1 shows the 3 established groups.

The prevalence of infection in the series was 5.2%. The majority in the three groups were male. The higher risk groups were older. Most of the patients admitted were due to fever associated with cough, dyspnea, or vomiting. These symptoms, together with a pathological chest X-ray, were what 4 motivated the hospital admission. Electrocardiographic or arrhythmic abnormalities were observed in none of the 20 patients in the series.

The change in immunosuppression performed in group 2 patients was well tolerated and there was no rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was close to 50% in group 2 and 100% in group 3.

The mean hospital stay was just over 2 weeks for hospitalized patients and almost 3 weeks for those admitted to critical care. The need for intubation identified a subgroup with a mortality of 100%, although there were only 2 cases.

Since the coronavirus epidemic began in Wuhan (China), this infection has spread throughout the world, reaching pandemic figures. The entire world population is susceptible to being infected, but there are some groups at higher risk due to their immunosuppression situation. Among these groups are heart transplants, in which management of prevention of rejection during an infection continues to be a challenge. When they are infected, it is advisable to modify the immunosuppressive treatment according to the severity of the infection to try to protect these patients as much as possible. In this series, 3 risk groups have been considered and it has been found that patients with few symptoms have a good evolution, when respiratory symptoms (pneumonia) are present it is possible to control the infection with changes in immunosuppression. However, when the patient requires orotracheal intubation, the chances of survival are slim.

In this series, the prevalence of COVID 19 infection in heart transplant patients is 5.2%. This coincides with the figures collected in the previous literature, although the prevalence is variable, (1) (2) in a country where the prevalence of infection in the general population is around 8%. (3) Most of the patients are men between the ages of 50 and 64 years, this being a similar profile to that described in other series of SARS-CoV-2 infected heart transplants. (2) None of the cases occurred early after transplantation. The reason for consulting these patients is the usual one in the general 5 population and published series of transplants, (2) being fever, dyspnea, cough, and/or vomiting. 30% of the patients did not require hospital admission, 60% did without the need for critical care, and only two patients required admission to the Critical Care Unit (10%), this being a distribution similar to those observed in previous studies. (1) Immunosuppression is common in this type of patient, (4) consisting of a CNI, MMF, and corticosteroids. The usual strategy followed in transplant patients infected with COVID 19 is to reduce immunosuppression. (2) (5) In this series, immunosuppression was not reduced in patients with a mild infection, the usual pattern was maintained, adjusting the CNI dose to the detected plasma levels. In group B, on the other hand, it was decided to reduce the CNI, in a similar way to that described in other series, (2) associating the substitution of MMF for the mTOR inhibitor EVE.

This change was made because EVE reduces the risk of infection by other viruses, such as cytomegalovirus (CMV), by regulating factors involved in several cellular functions crucial for CMV replication. (6) In contrast, MMF has traditionally been associated with viral infections and reactivations. (7) . The change in immunosuppression performed in these patients was well tolerated. Only two of the 20 patients had poor evolution from the respiratory point of view, requiring orotracheal intubation. In this case, we opted for the suspension of MMF without substitution by EVE, reducing the dose of CNI and maintaining or increasing if corticosteroid therapy was required. However, the two patients who reached this situation died. The mortality of the series was, therefore, 10%, lower than that reported in other registries, (1) (2) although the mortality in group 3 was 100% (2 patients).

In conclusion, it can be observed that a significant number of transplant patients are going to be affected by COVID-19. The management of the infection will depend on the severity of the infection and should be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiological situation, and treatment of the infection. 

Heart transplantation during the coronavirus disease 2019 pandemic: follow-up organization and characteristics of infected patients

COVID-19 in Heart Transplant Recipients

Prevalencia de infección por coronavirus SARS-CoV-2 en pacientes y profesionales de un hospital de media y larga estancia en España

Registro Español de Trasplante Cardiaco. XXXI Informe Oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología

Challenges in Heart Transplantation in the Era of COVID-19

Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection

Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?-A mini-review

Figure 1. Risk levels and guidelines for action in transplant patients with COVID 19